ProCE Banner Activity

CALIBRATE: Interim Week 28 Results of Long-acting Subcutaneous Lenacapavir in Treatment-Naive Patients

Slideset Download
Conference Coverage
After 2-week oral lead-in, treatment with oral or subcutaneous lenacapavir plus FTC/TAF associated with high rates of virologic suppression.

Released: July 24, 2021

Expiration: July 23, 2022

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

Merck Sharp & Dohme Corp.

ViiV Healthcare

Partners

IAS 2021

ProCE Banner